immunogenesis

1 known investors

ImmunoGenesis develops next-generation immunotherapies designed to treat immune-excluded tumors that resist current PD-1 inhibitors, using rational drug design to dismantle resistance mechanisms. The company focuses on oncology and immuno-oncology, with a pipeline of multifunctional therapeutics in clinical development.

BiotechHealthtechMedical Devices